Industry Focus
Healthcare: How Much Do Share Prices Matter In Big-Cap Biotech?
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 0:18:02
- Mais informações
Informações:
Sinopse
We compare Biogen's and Celgene's current valuations and consider what might be in store for Gilead Sciences now that its new hepatitis C drug is approved.
